The Zhitong Finance App learned that according to a research report released by Dongwu Securities, the specific provisions of the “Full Chain Implementation Plan to Support the Development of Innovative Drugs” are expected to be implemented in the near future. The innovative drug sector is expected to strengthen due to multiple catalysts such as the ESMO Conference, WCLC Conference, health insurance negotiations, and expectations of innovative drugs going overseas in the second half of the year. The conference where the “Plan” was adopted stated that it is necessary to strengthen policy guarantees throughout the chain, make good use of policies such as price management, medical insurance payment, commercial insurance, drug supply and use, investment and financing, etc., optimize review and approval and assessment mechanisms for medical institutions, and work together to promote the breakthrough development of innovative drugs.
This week and the beginning of the year, the pharmaceutical index rose 0.11% and -21%, respectively, compared to the Shanghai Index's excess earnings of 0.99% and -21%; stocks of traditional Chinese medicine (+1.54%) and chemicals (+1.37%) increased significantly this week, while stocks such as medical devices (-1.55%), biological products (-0.69%), and medical services (-0.82%) fell relatively large; this week, the largest increases were Pharmaceutical Holdings (+100%), Sunflower (+20.86%), and Dezhan Health (+16.35%) Reach Biotech (+15.44%), decline It ranked first in Northland (-14.33%), Kang Wei Century (-13.66%), Edith (-13.46%), and Mountain Wai (-12.58%). Characteristics of rising and falling performance: The pharmaceutical sector remained stable this week. Individual stocks of traditional Chinese medicine with small market capitalization rose significantly. Affected by the favorable weekend innovative drug policy, individual innovative drug stocks performed well on Friday.
The National Standing Committee reviewed and approved the “Implementation Plan to Support the Development of Innovative Drugs in the Whole Chain”, and the innovative drug sector is expected to strengthen: on July 5, the Executive Meeting of the State Council reviewed and approved the “Implementation Plan to Support the Development of Innovative Drugs in the Whole Chain”. The meeting pointed out that the development of innovative drugs is related to the development of the pharmaceutical industry and to people's health and welfare. The whole chain should strengthen policy guarantees, make good use of policies such as price management, medical insurance payment, commercial insurance, drug supply and use, investment and financing, etc., optimize review and approval and medical institution assessment mechanisms, and work together to promote the breakthrough development of innovative drugs. The specific provisions of the “Full Chain Implementation Plan to Support the Development of Innovative Drugs” are expected to be implemented in the near future. The superposition of the innovative drug sector is at a relative bottom in history. The second half of the year will have multiple catalysts such as the ESMO Conference, WCLC Conference, health insurance negotiations, and expectations of innovative drugs going overseas, and the innovative drug sector is expected to strengthen.
Specific configuration ideas: 1) Innovative medicine fields: Hehuang Pharmaceutical, Baijiao, Hengrui Pharmaceutical, HiCisco, Maiwei Biotech, Zejing Pharmaceutical-U, Dizhe Pharmaceutical, Connoya, etc.; 2) GLP1 industry chain fields: Borui Pharmaceuticals, Cinda Biotech, Sinovay, Noritai, Orient, etc.; 3) Field of traditional Chinese medicine: Taiji Group, Donga Ejiao, Zoli Pharmaceutical, Fangsheng Pharmaceutical, Kangrentang Yuan Pharmaceutical, etc.; 5) API field: Qianhong Pharmaceutical, Tonghe Pharmaceutical, Huahai Pharmaceutical, Tianyu Co., Ltd.; 6) Clinical and generic drug CRO: Nuo Seger, Tiger Pharmaceuticals, Baicheng Pharmaceutical, Sunshine Nuohe, etc.; 7) Pharmaceutical business: Jiuzhou Express, Sinopharm Group, etc.; 8) IVD fields: new industries, Antu Biotech, Ahuilong, etc.; 9) Medical consumables: Huitai Medical, Dabo Medical, Sanyou Medical, etc.; 10) Imitation medicine: Gebel, Enhua Pharmaceutical, Xianju Pharmaceutical, Cube Pharmaceuticals, Xinlitai, etc.; 11) Medical service fields: Aier Ophthalmology, Samsung Medical, Haijiao Medical, etc.; 11) Medical service fields: Aier Ophthalmology, Samsung Medical, Haijiao Medical, etc. Shengtang et al.; 12) Research service fields: Yakkang Biology, Optomax, etc. 13) Blood products field: Shanghai Rice, Tiantan Biology, Liberal Arts Biology, etc.
Risk warning: price reduction of drugs or consumables exceeds expectations; health insurance policy risks, etc.; product sales and development progress falls short of expectations.